Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹125.00
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.46B
Enterprise Value₹2.33B
Total Cash (Recent Filing)₹11.89M
Total Debt (Recent Filing)₹316.57M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraging / Stronger Balance SheetSizable reduction in debt materially lowers financial risk and interest burden, improving flexibility to fund operations or strategic investments. Over 2–6 months this supports credit access and reduces refinancing pressure, making recovery or growth investments more feasible.
Positive Operating Cash FlowConsistent positive operating cash flow shows the core pharmaceutical operations generate cash even during earnings volatility. This durable cash generation helps fund working capital and incremental investment, limiting short-term liquidity stress and easing reliance on external financing.
Diversified Pharma Business ModelA combined API and finished-dosage business serving domestic, institutional and export channels provides multiple revenue streams and manufacturing scale. This structural diversification reduces single-market dependence and supports longer-term resilience versus pure-play commodity exposure.
Bears Say
Revenue Decline And Profit ReversalA sharp swing from profit to substantial net loss signals fragile demand, pricing pressure, or cost control issues. Persistent revenue weakness undermines sustainable margins and makes multi-quarter recovery uncertain, constraining reinvestment and long-term growth planning.
Consistently Negative Free Cash FlowSustained negative free cash flow indicates the business requires external capital to fund capex or operations beyond operating cash generation. Over months this limits self-funding of growth, raises refinancing need, and increases exposure to funding cost or covenant risks.
Prior History Of Very High Leverage And Negative EquityPast episodes of extreme leverage and negative equity indicate structural capital-allocation or profitability problems. Even with recent improvement, such history can keep borrowing costs elevated and investor skepticism persistent, hindering durable access to favorable financing.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹125.00 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.46B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on May 25, 2026. The company reported -₹2.13 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.13.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 35,690,000 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of -₹2.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.162%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―